COVID-19 Response, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
Geospatial Research, Analysis, and Services Program (GRASP), Agency for Toxic Substances and Disease Registry, CDC, Atlanta, Georgia, USA.
Clin Infect Dis. 2022 Aug 24;75(1):e133-e143. doi: 10.1093/cid/ciac105.
Most studies on health disparities during the coronavirus disease 2019 (COVID-19) pandemic focused on reported cases and deaths, which are influenced by testing availability and access to care. This study aimed to examine severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody seroprevalence in the United States and its associations with race/ethnicity, rurality, and social vulnerability over time.
This repeated cross-sectional study used data from blood donations in 50 states and Washington, DC, from July 2020 through June 2021. Donor zip codes were matched to counties and linked with Social Vulnerability Index (SVI) and urban-rural classification. SARS-CoV-2 antibody seroprevalences induced by infection and infection-vaccination combined were estimated. Association of infection-induced seropositivity with demographics, rurality, SVI, and its 4 themes were quantified using multivariate regression models.
Weighted seroprevalence differed significantly by race/ethnicity and rurality, and increased with increasing social vulnerability. During the study period, infection-induced seroprevalence increased from 1.6% to 27.2% and 3.7% to 20.0% in rural and urban counties, respectively, while rural counties had lower combined infection- and vaccination-induced seroprevalence (80.0% vs 88.1%) in June 2021. Infection-induced seropositivity was associated with being Hispanic, non-Hispanic Black, and living in rural or more socially vulnerable counties, after adjusting for demographic and geographic covariates.
The findings demonstrated increasing SARS-CoV-2 seroprevalence in the United States across all geographic, demographic, and social sectors. The study illustrated disparities by race-ethnicity, rurality, and social vulnerability. The findings identified areas for targeted vaccination strategies and can inform efforts to reduce inequities and prepare for future outbreaks.
大多数关于 2019 年冠状病毒病(COVID-19)大流行期间健康差距的研究都集中在报告的病例和死亡人数上,这些数据受到检测的可用性和获得医疗的影响。本研究旨在检测美国严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)抗体血清阳性率及其与种族/民族、农村地区和社会脆弱性随时间的关系。
本重复横断面研究使用了 2020 年 7 月至 2021 年 6 月期间来自美国 50 个州和华盛顿特区的血液捐赠数据。根据邮政编码匹配各县,并与社会脆弱性指数(SVI)和城乡分类进行关联。估计由感染和感染-疫苗接种联合引起的 SARS-CoV-2 抗体血清阳性率。使用多变量回归模型量化感染引起的血清阳性与人口统计学、农村地区、SVI 及其 4 个主题的关联。
加权血清阳性率因种族/民族和农村地区而异,且随着社会脆弱性的增加而增加。在研究期间,农村和县的感染引起的血清阳性率分别从 1.6%增加到 27.2%和 3.7%增加到 20.0%,而农村县在 2021 年 6 月的感染和疫苗接种联合引起的血清阳性率较低(80.0%对 88.1%)。在调整了人口统计学和地理协变量后,感染引起的血清阳性与西班牙裔、非西班牙裔黑人以及生活在农村或社会脆弱性更高的县有关。
研究结果表明,美国所有地理、人口统计学和社会领域的 SARS-CoV-2 血清阳性率都在增加。该研究说明了种族-民族、农村地区和社会脆弱性方面的差异。研究结果确定了有针对性的疫苗接种策略的重点领域,并可以为减少不平等和为未来的疫情做好准备提供信息。